BY OUR PLATFORMS
BY THERAPEUTIC AREA
31 July 2018
We at ZeClinics strive to generate robust preclinical data to streamline the drug development process and often take pride in the biological relevance of our safety and efficacy assays.
But there are other downstream implications on later clinical phases we should also highlight: Take clinical research in children for instance, which calls for absolute certainty that no harm will be inflicted on the participants. We contribute our grain of sand with developmental studies, highly informative assays and improved early-phase predictability to help clinicians and parents make better-informed decisions.
This insightful article from Outsourcing-Pharma talks about the challenges of such pediatric trials, from regulatory requirements to social acceptance.
Click on the link and inform yourself!